Transfer learning enables prediction of CYP2D6 haplotype function
Authors: Gregory McInnes, Rachel Dalton, Katrin Sangkuhl, Michelle Whirl-Carrillo, Seung-been Lee, Philip S Tsao, Andrea Gaedigk, Russ B Altman, Erica L Woodahl
Journal: PLOS Computational Biology
Accepted: 2020-09-24T00:00:00Z


Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic gene whose protein product metabolizes more than 20% of clinically used drugs. Genetic variations in CYP2D6 are responsible for interindividual heterogeneity in drug response that can lead to drug toxicity and ineffective treatment, making CYP2D6 one of the most important pharmacogenes. Prediction of CYP2D6 phenotype relies on curation of literature-derived functional studies to assign a functional status to CYP2D6 haplotypes. As the number of large-scale sequencing efforts grows, new haplotypes continue to be discovered, and assignment of function is challenging to maintain. To address this challenge, we have trained a convolutional neural network to predict functional status of CYP2D6 haplotypes, called Hubble.2D6. Hubble.2D6 predicts haplotype function from sequence data and was trained using two pre-training steps with a combination of real and simulated data. We find that Hubble.2D6 predicts CYP2D6 haplotype functional status with 88% accuracy in a held-out test set and explains 47.5% of the variance in in vitro functional data among star alleles with unknown function. Hubble.2D6 may be a useful tool for assigning function to haplotypes with uncurated function, and used for screening individuals who are at risk of being poor metabolizers.
Author summary: CYP2D6 is an enzyme expressed in the liver that is responsible for metabolizing more than 20% of clinically used drugs. The gene that encodes CYP2D6 is highly polymorphic, with more than 130 haplotypes currently known. Genetic variants in CYP2D6 can drastically affect how an individual responds to pharmaceuticals metabolized by CYP2D6, affecting both drug safety and efficacy. Guidelines have been developed to help providers better prescribe drugs using CYP2D6 genotype, but because of the numerous variants that have been identified in CYP2D6 these guidelines aren’t suitable for all patients. The guidelines rely on the fact that the metabolic function of CYP2D6 haplotypes is known, however, this is not the case for more than half of all existing haplotypes. Currently, we rely on human curation of haplotypes to assess function, but as genome sequencing has become routine the number of haplotypes identified has grown rapidly, making human curation untenable. We have developed a system using machine learning, named Hubble.2D6, that seeks to address this problem by making predictions of metabolic function for CYP2D6 haplotypes. We trained a deep learning model using very little data by first pretraining the model on simulated data, allowing for the use of a complex model in a domain that is typically data limited. We find that Hubble.2D6 predicts haplotype function with high accuracy and that the predictions correlate with in vitro functional characterization. We believe that this predictive model can be helpful in assessing function of CYP2D6 haplotypes with unknown function, and that the method of pretraining on simulated data may be useful in other domains within genetics.